发明名称 Treating lung cancer using human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)
摘要 The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
申请公布号 US9505845(B2) 申请公布日期 2016.11.29
申请号 US201213442499 申请日期 2012.04.09
申请人 E. R. Squibb & Sons, L.L.C. 发明人 Terrett Jonathan Alexander;Lu Li-Sheng;Pan Chin
分类号 A61K39/395;C07K16/30;C07K16/40;A61K39/00 主分类号 A61K39/395
代理机构 Nelson Mullins Riley & Scarborough LLP 代理人 Nelson Mullins Riley & Scarborough LLP ;Remillard, Esq. Jane E.;Sloper, Esq. Jill Gorny
主权项 1. A method of treating a disease characterized by growth of tumor cells expressing PTK7, comprising administering to a subject a monoclonal antibody, or antigen-binding portion thereof, that specifically binds to human PTK7, wherein the antibody, or antigen-binding portion thereof, is linked to a therapeutic agent and comprises a heavy chain variable region CDR1 comprising SEQ ID NO:12; a heavy chain variable region CDR2 comprising SEQ ID NO:16; a heavy chain variable region CDR3 comprising SEQ ID NO:20; a light chain variable region CDR1 comprising SEQ ID NO:25; a light chain variable region CDR2 comprising SEQ ID NO:31; and a light chain variable region CDR3 comprising SEQ ID NO:37, in an amount effective to treat the disease, wherein the disease is lung cancer.
地址 Princeton NJ US